5 Blossom Street,

Boston,

MA,

US,

ZIP: 02114

Phone: (+1) 617 455 4188

Coming to Boston next May, the 2nd Induced Proximity-Based Drug Discovery Summit is the only industry and academic dedicated summit focused on exciting innovations and emerging case studies to establish novel strategies of identifying and optimizing drug design, physiological properties and therapeutic applications of induced proximity-based drugs.

This multidisciplinary summit will be gathering 100+ of the industry drug discovery leaders in large and small molecule disciplines to discuss how the phenomenon of induced proximity can be leveraged to precisely engineer biological outcomes such as post-translational modifications and degradation of high value targets in oncology and beyond.

With 25+ expert leaders from the likes of Amgen, Centrose Pharma, Stablix, Jerry Crabtree, and Amit Choudhary sharing their progress, don’t miss the chance to join the industry’s definitive in-person conference to make new connections and reconnect with your friends and colleagues.

Tickets    https://go.evvnt.com/969482-2?pid=1052
Brochure https://go.evvnt.com/969482-3?pid=1052

Prices:
Drug Developer Pricing - Conference Only USD 2999.00
Drug Developer Pricing - Conference + 1 Workshop USD 3648.00
Drug Developer Pricing - Conference + 2 Workshops USD 4297.00
Academic Pricing - Conference Only USD 2599.00
Academic Pricing - Conference + 1 Workshop USD 3148.00
Academic Pricing - Conference + 2 Workshops USD 3697.00
Standard Pricing - Conference Only USD 3599.00
Standard Pricing - Conference + 1 Workshop USD 4348.00
Standard Pricing - Conference + 2 Workshops USD 5097.00

Category: Conferences | Science, Health & Medicine | Pharmaceuticals | Drug Discovery

Omid Vafa, CBO, Ancora Biotech, Ed Ha, Head of Chemistry & Bioconjugation, Angiex, Manish, Hudlikar Scientist, Chemistry & Bioconjugates, Angiex, Nancy K Pryer, CSO, Ambagon Therapeutics, Ryan Potts, Head of Induced Proximity Platform, Amgen, James Prudent, CEO, Centrose Pharma, Behnam Nabet, Assistant Professor, Fred Hutchinson Cancer Research Center, Greg Verdine, Co-Founder & CEO, Fog Pharma, Binghe Wang, Regents Professor and Georgia Research Alliance Eminent Scholar, Georgia State University, Amit Choudhary, Assistant Professor of Medicine, Harvard Medical School, Christina Woo, Associate Professor, Harvard University, Charles Lin, SVP Biology, Kronos Bio, Anthony Rullo, Assistant Professor, McMaster University, Kevin Foley, CSO, Ranok Therapeutics, Nan Ji, CEO, PAQ Therapeutics, Alun Bermingham, Senior Director Discovery Sciences, Revolution Medicines, Matthew Disney, Professor, Scripps Research, Scott A. Kanner, Co-founder & Head of Platform Development, Stablix, Tommaso Cupido, Assistant Faculty, St Jude Children’s Research Hospital, Jerry Crabtree, David Korn Professor, Stanford University Medical School, Jesse J. Chen, Co-Founder & CTO, Triana Biomedicines, Goutham Narla, Professor of Internal Medicine and Human Genetics, Division Chief of Genetic Medicine, The University of Michigan, Nate Hathaway, Associate Professor, The University of North Carolina at Chapel Hill, George M. Burslem, Assistant Professor, University of Pennsylvania, Katarina Pance, PhD Candidate (Jim Wells Lab), University of California, San Francisco, William Pomerantz, Associate Professor, University of Minnesota